Tumor Treating Fields (TTFields), an approved therapy for glioblastoma (GBM) and
malignant mesothelioma, employ noninvasive application of low-intensity, intermediate …

Glioblastoma (GBM) is a devastating brain tumor with poor prognosis despite advances in
surgery, radiation, and chemotherapy. Survival of patients with glioblastoma remains poor …

We performed a treatment-based analysis of data from the pivotal phase III trial of the
NovoTTF-100A System™ versus best physician's choice (BPC) chemotherapy in patients …

Since the discovery that cGAS/STING recognizes endogenous DNA released from dying
cancer cells and induces type I interferon and antitumor T cell responses, efforts to …

Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer.
Median overall survival (OS) for newly diagnosed patients is only about 12 to 18 months …

Glioblastoma is both the most common and most lethal primary CNS malignancy in adults,
accounting for 45.6% of all malignant CNS tumors, with a 5-year survival rate of only 5.0 …

Aim: To estimate the mean lifetime survival benefit, an essential component of health
economic evaluations in oncology, of adding tumor treating fields (TTFields) to maintenance …

Elimination of serious side effects is a desired feature of cancer therapy. Alternating electric
field treatment is one approach to the non-invasive treatment of cancer. The efficacy and …

Tumor-treating fields (TTFields) therapy is a relatively new treatment approach for malignant
gliomas. We evaluated if amino acid PET can detect an objective metabolic response to …

Nowadays, cancer disease is continuously identified as the leading cause of mortality
worldwide. Cancer chemotherapeutic agents have been continuously developing to achieve …